NeuroBo’s DA-1726 Shows Promise in Obesity Trial Phase 1

NeuroBo Pharmaceuticals ( (NRBO) ) just unveiled an update.

NeuroBo Pharmaceuticals, Inc. has announced promising results from Part 1 of the Phase 1 clinical trial for its obesity treatment, DA-1726, which showcases favorable safety, tolerability, and dose-linear pharmacokinetics. The trial, involving 45 obese yet otherwise healthy participants, reported no serious adverse events, setting a positive stage for the future phases of the research. Eagerly anticipated is the top-line data from the ongoing multiple ascending dose study, as well as an early proof of concept from the planned Part 3 of the trial, which collectively aim to position DA-1726 as a potentially superior obesity treatment option.

Learn more about NRBO stock on TipRanks’ Stock Analysis page.